Benign Prostatic Hyperplasia Market By Treatment Type (Pharmacological Treatment {Alpha Blockers, 5-alpha-reductase Inhibitors, Combination Therapy, Phytotherapy}, Minimally Invasive Procedures {UroLift System, Rezūm Therapy, Prostatic Artery Embolization}, Surgical Treatment {Transurethral Resection of the Prostate, Laser Surgery, Open Prostatectomy}), By Dosage Form (Oral Immediate-Release, Oral Extended-Release, Others), By Diagnostic Method (Digital Rectal Exam, Prostate-Specific Antigen Test, Ultrasound, Urinary Flow Study, Cystoscopy), By End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Benign Prostatic Hyperplasia Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Rising geriatric male population increasing BPH prevalence and demand for effective treatments.

3.2.2. Advancements in minimally invasive procedures improve outcomes and patient preference over traditional surgeries.

3.2.3. Growing awareness and early diagnosis rates fuel demand for pharmacological and procedural therapies.

3.3. Key industry pitfalls & challenges

3.3.1. High cost of advanced therapies limits access in low- and middle-income regions.

3.3.2. Side effects and long-term dependency on drugs discourage consistent treatment adherence.

3.3.3. Limited availability of skilled professionals for specialized BPH procedures in rural or remote areas.

3.4. Market Opportunities

3.4.1. Technological innovations in laser and implantable devices promise better, safer BPH management.

3.4.2. Untapped emerging markets offer potential for expansion of low-cost and alternative treatment options.

3.4.3. Personalized medicine and biomarker-based approaches can improve BPH treatment effectiveness and patient outcomes.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Benign Prostatic Hyperplasia Market, Treatment Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Treatment Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Pharmacological Treatment

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.2. Alpha Blockers

4.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3. 5-alpha-reductase Inhibitors

4.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.4. Combination Therapy

4.2.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.5. Phytotherapy

4.2.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Minimally Invasive Procedures

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.2. UroLift System

4.3.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.3. Rezūm Therapy

4.3.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.4. Prostatic Artery Embolization

4.3.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Surgical Treatment

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4.2. Transurethral Resection of the Prostate

4.4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4.3. Laser Surgery

4.4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4.4. Open Prostatectomy

4.4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Benign Prostatic Hyperplasia Market, Dosage Form Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Dosage Form, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Oral Immediate-Release

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Oral Extended-Release

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Others

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Benign Prostatic Hyperplasia Market, Diagnostic Method Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Diagnostic Method, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Digital Rectal Exam

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Prostate-Specific Antigen Test

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Ultrasound

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Urinary Flow Study

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.6. Cystoscopy

6.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Benign Prostatic Hyperplasia Market, End-user Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By End-user, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Hospitals

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Ambulatory Surgical Centers

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Specialty Clinics

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Homecare

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.6. Others

7.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Benign Prostatic Hyperplasia Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

8.2.2. North America Market Revenue, By Treatment Type, 2025-2035

8.2.3. North America Market Revenue, By Dosage Form, 2025-2035

8.2.4. North America Market Revenue, By Diagnostic Method, 2025-2035

8.2.5. North America Market Revenue, By End-user, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Treatment Type, 2025-2035

8.2.6.2. U.S. Market Revenue, By Dosage Form, 2025-2035

8.2.6.3. U.S. Market Revenue, By Diagnostic Method, 2025-2035

8.2.6.4. U.S. Market Revenue, By End-user, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Treatment Type, 2025-2035

8.2.7.2. Canada Market Revenue, By Dosage Form, 2025-2035

8.2.7.3. Canada Market Revenue, By Diagnostic Method, 2025-2035

8.2.7.4. Canada Market Revenue, By End-user, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

8.3.2. Europe Market Revenue, By Treatment Type, 2025-2035

8.3.3. Europe Market Revenue, By Dosage Form, 2025-2035

8.3.4. Europe Market Revenue, By Diagnostic Method, 2025-2035

8.3.5. Europe Market Revenue, By End-user, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Treatment Type, 2025-2035

8.3.6.2. Germany Market Revenue, By Dosage Form, 2025-2035

8.3.6.3. Germany Market Revenue, By Diagnostic Method, 2025-2035

8.3.6.4. Germany Market Revenue, By End-user, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Treatment Type, 2025-2035

8.3.7.2. France Market Revenue, By Dosage Form, 2025-2035

8.3.7.3. France Market Revenue, By Diagnostic Method, 2025-2035

8.3.7.4. France Market Revenue, By End-user, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Treatment Type, 2025-2035

8.3.8.2. U.K. Market Revenue, By Dosage Form, 2025-2035

8.3.8.3. U.K. Market Revenue, By Diagnostic Method, 2025-2035

8.3.8.4. U.K. Market Revenue, By End-user, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Treatment Type, 2025-2035

8.3.9.2. Italy Market Revenue, By Dosage Form, 2025-2035

8.3.9.3. Italy Market Revenue, By Diagnostic Method, 2025-2035

8.3.9.4. Italy Market Revenue, By End-user, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Treatment Type, 2025-2035

8.3.10.2. Spain Market Revenue, By Dosage Form, 2025-2035

8.3.10.3. Spain Market Revenue, By Diagnostic Method, 2025-2035

8.3.10.4. Spain Market Revenue, By End-user, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Treatment Type, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Dosage Form, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Diagnostic Method, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By End-user, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

8.4.2. Asia Pacific Market Revenue, By Treatment Type, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Dosage Form, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Diagnostic Method, 2025-2035

8.4.5. Asia Pacific Market Revenue, By End-user, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Treatment Type, 2025-2035

8.4.6.2. China Market Revenue, By Dosage Form, 2025-2035

8.4.6.3. China Market Revenue, By Diagnostic Method, 2025-2035

8.4.6.4. China Market Revenue, By End-user, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Treatment Type, 2025-2035

8.4.7.2. Japan Market Revenue, By Dosage Form, 2025-2035

8.4.7.3. Japan Market Revenue, By Diagnostic Method, 2025-2035

8.4.7.4. Japan Market Revenue, By End-user, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Treatment Type, 2025-2035

8.4.8.2. India Market Revenue, By Dosage Form, 2025-2035

8.4.8.3. India Market Revenue, By Diagnostic Method, 2025-2035

8.4.8.4. India Market Revenue, By End-user, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Treatment Type, 2025-2035

8.4.9.2. Australia Market Revenue, By Dosage Form, 2025-2035

8.4.9.3. Australia Market Revenue, By Diagnostic Method, 2025-2035

8.4.9.4. Australia Market Revenue, By End-user, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Treatment Type, 2025-2035

8.4.10.2. South Korea Market Revenue, By Dosage Form, 2025-2035

8.4.10.3. South Korea Market Revenue, By Diagnostic Method, 2025-2035

8.4.10.4. South Korea Market Revenue, By End-user, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Treatment Type, 2025-2035

8.4.11.2. Singapore Market Revenue, By Dosage Form, 2025-2035

8.4.11.3. Singapore Market Revenue, By Diagnostic Method, 2025-2035

8.4.11.4. Singapore Market Revenue, By End-user, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Treatment Type, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Dosage Form, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Diagnostic Method, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

8.5.2. Latin America Market Revenue, By Treatment Type, 2025-2035

8.5.3. Latin America Market Revenue, By Dosage Form, 2025-2035

8.5.4. Latin America Market Revenue, By Diagnostic Method, 2025-2035

8.5.5. Latin America Market Revenue, By End-user, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Treatment Type, 2025-2035

8.5.6.2. Brazil Market Revenue, By Dosage Form, 2025-2035

8.5.6.3. Brazil Market Revenue, By Diagnostic Method, 2025-2035

8.5.6.4. Brazil Market Revenue, By End-user, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Treatment Type, 2025-2035

8.5.7.2. Argentina Market Revenue, By Dosage Form, 2025-2035

8.5.7.3. Argentina Market Revenue, By Diagnostic Method, 2025-2035

8.5.7.4. Argentina Market Revenue, By End-user, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Treatment Type, 2025-2035

8.5.8.2. Mexico Market Revenue, By Dosage Form, 2025-2035

8.5.8.3. Mexico Market Revenue, By Diagnostic Method, 2025-2035

8.5.8.4. Mexico Market Revenue, By End-user, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Treatment Type, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Dosage Form, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Diagnostic Method, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By End-user, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

8.6.2. MEA Market Revenue, By Treatment Type, 2025-2035

8.6.3. MEA Market Revenue, By Dosage Form, 2025-2035

8.6.4. MEA Market Revenue, By Diagnostic Method, 2025-2035

8.6.5. MEA Market Revenue, By End-user, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Treatment Type, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Dosage Form, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Diagnostic Method, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By End-user, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Treatment Type, 2025-2035

8.6.7.2. South Africa Market Revenue, By Dosage Form, 2025-2035

8.6.7.3. South Africa Market Revenue, By Diagnostic Method, 2025-2035

8.6.7.4. South Africa Market Revenue, By End-user, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Treatment Type, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Dosage Form, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Diagnostic Method, 2025-2035

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

9. Company Profile

9.1. GlaxoSmithKline plc

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Astellas Pharma Inc.

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. Abbott Laboratories

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Pfizer Inc.

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Merck & Co., Inc.

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. Eli Lilly and Company

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. Sanofi

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. Teva Pharmaceutical Industries Ltd.

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. Boehringer Ingelheim

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. Allergan (now part of AbbVie)

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Novartis AG

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. Bayer AG

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Ferring Pharmaceuticals

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. Teleflex Incorporated

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. Boston Scientific Corporation

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis